Search

Your search keyword '"R Katayama"' showing total 238 results

Search Constraints

Start Over You searched for: Author "R Katayama" Remove constraint Author: "R Katayama"
238 results on '"R Katayama"'

Search Results

101. Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.

102. Solubilization of Paclitaxel by Self-Assembled Amphiphilic Phospholipid-Mimetic Polymers with Varied Hydrophobicity.

103. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.

104. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.

105. Chromatin structure-dependent histone incorporation revealed by a genome-wide deposition assay.

106. Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

107. A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation.

108. Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor Treatment.

109. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

110. Metolazone upregulates mitochondrial chaperones and extends lifespan in Caenorhabditis elegans.

111. The characteristic response of domestic cats to plant iridoids allows them to gain chemical defense against mosquitoes.

112. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.

113. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.

114. Characterization of the Hydration Process of Phospholipid-Mimetic Polymers Using Air-Injection-Mediated Liquid Exclusion Methods.

115. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.

116. Dependence of the V/III Ratio on Indium Incorporation in InGaN Films Grown by Metalorganic Vapour Phase Epitaxy.

117. Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease.

118. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.

119. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

120. Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.

121. Formation of Hydrophobic Domains on the poly(MPC- co -Dodecyl Methacrylate)-Coated Surface Recognized by Macrophage-like Cells.

122. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

123. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

124. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.

125. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

126. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.

127. Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells.

128. Lysyl oxidase-like protein secreted from an acidophilic red alga, Cyanidium caldarium .

129. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey ( Macaca fascicularis ).

130. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.

131. 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.

132. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

133. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.

134. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.

135. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.

136. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.

137. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.

138. Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.

139. APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.

140. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.

141. Nanometer scale fabrication and optical response of InGaN/GaN quantum disks.

142. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

143. Region-specific growth restriction of brain following preterm birth.

144. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

145. Series: Practical Evaluation of Clinical Image Quality (2): Image Quality Measurements for Digital Radiography Systems.

146. Series: Practical Evaluation of Clinical Image Quality (1):Image Quality Verification of Digital Radiography.

147. Series: Practical Evaluation of Clinical Image Quality (3): Subjective Evaluation of Image Quality in Digital Radiography Systems.

148. Series: Practical Evaluation of Clinical Image Quality (4): Determination of Image Quality in Digital Radiography System.

149. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

150. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Catalog

Books, media, physical & digital resources